With IXHL's late stage trials on both sleep apnea and rheumatoid arthritis, along with a strong patent portfolio and market cap of only $30M, I'm bett...
Read
More
With IXHL's late stage trials on both sleep apnea and rheumatoid arthritis, along with a strong patent portfolio and market cap of only $30M, I'm betting on it as a potential 10-bagger if the phase 2b/3 readouts are positive.